ETPrime

Emcure Pharmaceuticals Share Price

  • 1,362.70-1.80 (-0.14%)
  • Volume: 4,412
  • Live
  • Last Updated On: 16 Oct, 2025, 09:51 AM IST
High: "1740.00",Open: "1628.00",Low: "1530.00",
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Emcure Pharmaceuticals Share Price
  • 1,362.70-1.80 (-0.14%)
  • Volume: 4,412
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

STRONG BUY

Mean Recos by
5 Analysts

0

0

1

0

4

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Key Metrics

PE Ratio
(x)		34.75
EPS - TTM
(₹)		39.27
MCap
(₹ Cr.)		25,858.41
Sectoral MCap Rank
21
PB Ratio
(x)		5.57
Div Yield
(%)		0.22
Face Value
(₹)		10.00
Beta

Beta

1 Month-
3 Months-
6 Months-
1 Year-
3 Years-

-
VWAP
(₹)		1,365.69
52W H/L
(₹)
1,532.95 / 889.00

Emcure Pharmaceutica share price insights

View All

  • Since its listing, only 3.16 % trading sessions saw intraday gains higher than 5 % .

  • Company's annual revenue growth of 18.58% outperformed its 3 year CAGR of 10.29%. (Source: Consolidated Financials)

  • 50 day moving crossover appeared yesterday. Average price gain of 7.77% within 30 days of this signal in last 5 years.

  • Company has spent 2.23% of its operating revenues towards interest expenses and 18.32% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Emcure Pharmaceuticals Ltd. share price moved down by -0.11% from its previous close of Rs 1,364.50. Emcure Pharmaceuticals Ltd. stock last traded price is 1,363.10

    Share PriceValue
    Today/Current/Last1,363.10
    Previous Day1,364.501,360.80

InsightsEmcure Pharmaceutica

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Emcure Pharmaceutica Share Price Returns

    1 Day-0.14%
    1 Week-2.37%
    1 Month0.17%
    3 Months0.01%
    1 Year-8.3%
    3 YearsN.A.
    5 YearsN.A.

    ET Stock ScreenersTop Score Companies

    Check whether Emcure Pharmaceutica belongs to analysts' top-rated companies list?

    View Stock Screeners

    Emcure Pharmaceutica News & Analysis

    View all Emcure Pharmaceutica Share News & Announcements

    Emcure Pharmaceutica Share Recommendations

    Recent Recos

    STRONG BUY

    Current

    Mean Recos by 5 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy

    That's all for Emcure Pharmaceutica recommendations. Check out other stock recos.

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy4432
    Buy----
    Hold1111
    Sell----
    Strong Sell----
    # Analysts5543
    View all Stock Recommendations

    Emcure Pharmaceutica Financials

    • Insights

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 18.58% outperformed its 3 year CAGR of 10.29%. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent 2.23% of its operating revenues towards interest expenses and 18.32% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income2,104.232,120.701,966.532,037.641,838.58
      Total Income Growth (%)-0.787.84-3.4910.833.11
      Total Expenses1,786.721,821.061,704.831,718.011,572.41
      Total Expenses Growth (%)-1.896.82-0.779.263.07
      EBIT317.51299.64261.70319.63266.17
      EBIT Growth (%)5.9714.50-18.1320.093.38
      Profit after Tax (PAT)206.95188.96153.72194.57144.08
      PAT Growth (%)9.5222.92-20.9935.0425.11
      EBIT Margin (%)15.0914.1313.3115.6914.48
      Net Profit Margin (%)9.848.917.829.557.84
      Basic EPS (₹)10.929.978.1210.337.95
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income1,118.101,300.581,048.221,159.561,002.80
      Total Income Growth (%)-14.0324.08-9.6015.637.06
      Total Expenses931.891,090.46961.041,008.81910.18
      Total Expenses Growth (%)-14.5413.47-4.7310.847.71
      EBIT186.21210.1287.18150.7692.62
      EBIT Growth (%)-11.38141.02-42.1762.781.01
      Profit after Tax (PAT)122.79139.5650.2086.9240.45
      PAT Growth (%)-12.02177.98-42.24114.9139.57
      EBIT Margin (%)16.6516.168.3213.009.24
      Net Profit Margin (%)10.9810.734.797.504.03
      Basic EPS (₹)6.487.372.654.622.23
      Quarterly | Annual FY 2025 FY 2024 FY 2023
      Total Revenue7,963.266,715.246,031.72
      Total Revenue Growth (%)18.5811.331.91
      Total Expenses6,981.535,978.085,278.36
      Total Expenses Growth (%)16.7913.266.71
      Profit after Tax (PAT)681.33498.18532.02
      PAT Growth (%)36.76-6.36-19.66
      Operating Profit Margin (%)14.6514.6316.15
      Net Profit Margin (%)8.627.488.88
      Basic EPS (₹)36.4327.5429.42
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue4,500.733,635.913,232.443,519.923,265.57
      Total Revenue Growth (%)23.7912.48-8.177.7929.93
      Total Expenses4,073.023,426.693,013.952,903.502,689.84
      Total Expenses Growth (%)18.8613.693.807.9419.84
      Profit after Tax (PAT)317.13160.83160.06446.81420.48
      PAT Growth (%)97.180.48-64.186.26139.99
      Operating Profit Margin (%)12.3310.7312.4022.4822.16
      Net Profit Margin (%)7.234.595.1513.1913.33
      Basic EPS (₹)16.958.898.8524.7123.25

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023
      Total Assets8,232.727,806.166,672.53
      Total Assets Growth (%)5.4616.9910.04
      Total Liabilities3,591.174,684.404,022.87
      Total Liabilities Growth (%)-23.3416.441.86
      Total Equity4,641.553,121.772,649.66
      Total Equity Growth (%)48.6817.8225.33
      Current Ratio (x)1.711.331.27
      Total Debt to Equity (x)0.160.710.88
      Contingent Liabilities474.42378.81176.53
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets5,416.114,756.934,615.854,323.184,863.20
      Total Assets Growth (%)13.863.066.77-11.1025.63
      Total Liabilities2,391.752,821.832,773.982,610.652,561.42
      Total Liabilities Growth (%)-15.241.726.261.9230.91
      Total Equity3,024.361,935.101,841.871,712.532,301.77
      Total Equity Growth (%)56.295.067.55-25.6020.23
      Current Ratio (x)1.431.001.071.101.24
      Total Debt to Equity (x)0.220.730.910.920.57
      Contingent Liabilities303.72244.0866.5689.1145.52

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 94.0 cr for investing activities which is an YoY decrease of 86.81%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023
      Net Cash flow from Operating Activities851.711,097.24746.85
      Net Cash used in Investing Activities-94.00-712.51-467.69
      Net Cash flow from Financing Activities-813.96-164.21-145.40
      Net Cash Flow-58.30218.52133.64
      Closing Cash & Cash Equivalent-14.3143.99-174.53
      Closing Cash & Cash Equivalent Growth (%)-132.53-125.21-43.37
      Total Debt/ CFO (x)0.861.902.94
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities558.29584.97505.37427.71774.87
      Net Cash used in Investing Activities-435.61-171.08-270.44-189.00-831.16
      Net Cash flow from Financing Activities-49.25-287.75-54.52-342.9630.97
      Net Cash Flow71.38124.15180.30-309.06-29.94
      Closing Cash & Cash Equivalent-17.53-88.91-213.05-393.35-84.29
      Closing Cash & Cash Equivalent Growth (%)-80.29-58.27-45.84366.6855.09
      Total Debt/ CFO (x)1.172.423.303.681.68

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023
      Return on Equity (%)15.3216.8721.27
      Return on Capital Employed (%)20.8021.2026.46
      Return on Assets (%)8.276.387.97
      Interest Coverage Ratio (x)8.775.435.74
      Asset Turnover Ratio (x)0.980.920.94
      Price to Earnings (x)29.85--
      Price to Book (x)4.57--
      EV/EBITDA (x)13.68--
      EBITDA Margin (%)19.5219.3220.49
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)10.488.318.6926.0918.26
      Return on Capital Employed (%)14.6214.2814.7031.8722.74
      Return on Assets (%)5.853.383.4610.338.64
      Interest Coverage Ratio (x)6.783.493.386.396.93
      Asset Turnover Ratio (x)0.860.750.700.740.72
      Price to Earnings (x)64.10----
      Price to Book (x)6.72----
      EV/EBITDA (x)27.39----
      EBITDA Margin (%)17.4716.5818.1427.3727.12

    Financial InsightsEmcure Pharmaceutica

    • Income (P&L)
    • Cash Flow

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 18.58% outperformed its 3 year CAGR of 10.29%. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent 2.23% of its operating revenues towards interest expenses and 18.32% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 94.0 cr for investing activities which is an YoY decrease of 86.81%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Emcure Pharmaceutica Share Price Forecast

    • Get multiple analysts’ prediction on Emcure Pharmaceutica

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Emcure Pharmaceutica

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Emcure Pharmaceutica

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Emcure Pharmaceutica Technicals

    • Bullish / Bearish signals for Emcure Pharmaceutica basis selected technical indicators and moving average crossovers.

      14 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 15 Oct 2025

      14D EMA: 1364.06

      Last 4 Buy Signals:3 Oct 2025
      Date7 days Gain/Loss %
      3 Oct 20258.13%
      12 Aug 20256.43%
      4 Aug 20252.74%
      10 Jul 20258.71%

      Average price gain of 3.97% within 7 days of Bullish signal in last 5 years

      20 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 15 Oct 2025

      20D EMA: 1362.70

      Last 4 Buy Signals:3 Oct 2025
      Date7 days Gain/Loss %
      3 Oct 20258.13%
      11 Aug 20257.85%
      4 Aug 20252.74%
      11 Jul 20257.52%

      Average price gain of 4.55% within 7 days of Bullish signal in last 5 years

      Show More
    • 45%
      Positive Movement since
      1st Jan 2005 on basis
      55%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic1377.071388.731409.231368.231356.571347.731327.23

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR43.0543.1343.30

    Emcure Pharmaceutica Peer Comparison

    Peers InsightsEmcure Pharmaceutica

      Do you find these insights useful?

      • hate it

      • meh

      • love it

      Emcure Pharmaceutica Shareholding Pattern

      • Loading...
        Showing Emcure Pharmaceutica Shareholding as on Jun 2025
        CategoryJun 2025Mar 2025Dec 2024Sep 2024
        Promoters77.9177.9277.9478.08
        Pledge0.040.040.000.00
        FII2.863.063.052.90
        DII2.843.443.873.96
        Mutual Funds2.342.733.103.30
        Others16.3915.5715.1415.06
      • Showing Shareholding as on Jun 2025
        CategoryNo. of SharesPercentage% Change QoQ
        Promoters14,76,49,28277.91 %-0.01
        Pledge60,0000.04 %0.00
        FII54,10,7952.86 %-0.20
        DII53,85,5262.84 %-0.60
        MF44,31,1552.34 %-0.39
        Others3,10,62,74416.39 %0.81

      Emcure Pharmaceutica MF Ownership

      MF Ownership as on 30 September 2025

      View all Mutual Fund Schemes
      Top Searches:
      Emcure Pharmaceutica News Emcure Pharmaceutica Quarterly Results Emcure Pharmaceutica Dividend Emcure Pharmaceutica Q1 ResultsEmcure Pharmaceutica Q2 ResultsEmcure Pharmaceutica Q3 ResultsEmcure Pharmaceutica Q4 Results

      Emcure Pharmaceutica Corporate Actions

      • Meeting DateAnnounced onPurposeDetails
        Aug 28, 2025Aug 04, 2025AGM-
        Aug 07, 2025Jul 28, 2025Board MeetingQuarterly Results
        May 22, 2025May 13, 2025Board MeetingAudited Results & Final Dividend
        Feb 06, 2025Jan 24, 2025Board MeetingQuarterly Results
        Dec 25, 2024Nov 25, 2024POM-
      • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
        Final30%3.0Aug 14, 2025May 22, 2025

      • No other corporate actions details are available.

      About Emcure Pharmaceutica

      Emcure Pharmaceuticals Ltd., incorporated in the year 1981, is a Small Cap company (having a market cap of Rs 25,858.41 Crore) operating in Pharmaceuticals sector. Emcure Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the year ending 31-Mar-2025. Show More

      • Executives

      • Auditors

      • BM

        Berjis Minoo Desai

        Chairman & Non-Exe.Director
        SR

        Satish Ramanlal Mehta

        Managing Director & CEO
        MK

        Mukund Keshao Gurjar

        Whole Time Director
        NV

        Namita Vikas Thapar

        Whole Time Director
        Show More
      • B S R & Co. LLP

      Industry

      Pharma - Indian

      Key Indices Listed on

      Nifty 500, BSE MidCap, Nifty500 Healthcare, + 7 more

      Address

      Plot No. P-1 & P-2,IT-BT Park, Phase II,M.I.D.C., Hinjawadi,Pune, Maharashtra - 411057

      Contact

      [email protected]

      http://www.emcure.com

      More Details

      Trending in Markets

      Top Gainers As on 09:49 AM | 16 Oct 2025

      ITI Ltd348.80
      23.70 (7.30%)
      Craftsman Automation6,743.00
      319.00 (4.97%)
      Alok Industries18.28
      0.86 (4.88%)
      FACT921.00
      40.40 (4.59%)
      Whirlpool India1,231.00
      48.00 (4.06%)

      Top Losers As on 09:47 AM | 16 Oct 2025

      KEI Industries4,200.40
      -220.21 (-4.99%)
      HDFC Life740.20
      -20.95 (-2.76%)
      Tata Investment916.00
      -25.00 (-2.66%)
      Anant Raj645.50
      -17.05 (-2.58%)
      Max Financial1,576.00
      -33.10 (-2.06%)

      DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

      DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

      By using this site, you agree to the Terms of Service and Privacy Policy.

      Business News›Markets›Stocks›Stock Price Quotes›Emcure Pharmaceutica Share Price
      The Economic Times
      BrowseCompanies: